Colorado

The exclusion is in the regulation itself. 10 CCR 2505-10 8.800.4.B provides that under 42 U.S.C. 1396r-8(d)(2) certain drugs may be excluded, and then lists: "The following are excluded from coverage: a. Agents when used for anorexia or weight loss;" — alongside agents for fertility, cosmetic purposes and hair growth. Agents used for weight GAIN sit in the separate list of drugs "covered with restrictions."

10 CCR 2505-10 §8.800.4.B, Code of Colorado Regulations, Medical Services Board · source

The pharmacy benefit's own criteria document restates it as a class. Appendix P lists a class headed "ANOREXIANTS" and says "Medications prescribed for use for weight loss are not a covered benefit," naming Adipex-P, Belviq, Contrave, Lomaira, phentermine, Qsymia, Saxenda and Xenical. The version read carries "DUR Quarterly Revisions Effective 10/01/2026" and "Revised 08/31/2026" on its face.

Colorado Department of Health Care Policy & Financing, Appendix P (Health First Colorado Pharmacy Benefit), effective October 2026 · source

The drug list repeats the rule in the words that matter: "Note: Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved." The same note appears against the amylin class. So the drugs are on the list, and the reason is what is refused.

Colorado Department of Health Care Policy and Financing, Preferred Drug List, effective October 1, 2026, effective October 2026 · source

The sleep apnea route is the widest door and it is a long list. Zepbound may be approved where the member is 18 or older, has "a documented diagnosis of moderate to severe obstructive sleep apnea (OSA)," has "a BMI ≥30 kg/m2 indicating obesity documented in medical chart notes," has a diagnosis confirmed by an FDA-approved sleep test, has had a polysomnogram "with a documented result of Apnea-Hypopnea Index (AHI) ≥15 events/hour," is not pregnant or planning to be, is prescribed "by or in consultation with a neurologist, pulmonologist, otolaryngologist, or other sleep medicine specialist," is engaged in diet and exercise, and "has failed a 6-month trial of continuous positive airway pressure (CPAP) or has a contraindication to the use of PAP therapy." Reauthorization for a year needs an in-person re-evaluation and documented clinical improvement.

Colorado Department of Health Care Policy and Financing, Preferred Drug List, effective October 1, 2026, effective October 2026 · source

The cardiovascular route turns partly on a diagnosis you must NOT have. Wegovy may be approved where the member is 18 or older, "has established cardiovascular disease (history of myocardial infarction, stroke, or symptomatic peripheral arterial disease) and either obesity or overweight (defined as a BMI ≥25 kg/m2)," AND "does not have a diagnosis of Type 2 diabetes," and where the drug is prescribed to reduce cardiovascular events. A third route covers GLP-1s FDA-indicated for MASH at stage F2 to F3 fibrosis, prescribed by or with a named specialist.

Colorado Department of Health Care Policy and Financing, Preferred Drug List, effective October 1, 2026, effective October 2026 · source

The last change eased access inside the sleep apnea route. The September 2026 provider bulletin states that "Effective October 1, 2026, the Zepbound multidose KwikPen formulation will be changed to preferred status with criteria listed on the Preferred Drug List (PDL). The weekly single-use Zepbound injection pens will remain non-preferred," and that "Members with current prior authorization (PA) approval on file for the weekly single-use Zepbound pen formulation will automatically receive PA approval for the preferred Zepbound KwikPen to ease transition to the preferred product."

Colorado Department of Health Care Policy & Financing, Provider Bulletin B2600542, September 2026, effective October 2026 · source

Colorado's drug list says on its own face that it does not reach every member: "The PDL applies to Medicaid fee-for-service members. It does not apply to members enrolled in Rocky Mountain Health HMO or Denver Health Medicaid Choice." Those two plans publish their own formularies, which we did not open. Nothing on this page describes what they cover.

Colorado Department of Health Care Policy and Financing, Preferred Drug List, effective October 1, 2026, effective October 2026 · source

Colorado's hearing window is 60 days and it runs from the notice date. The rule requires the request be filed with the Office of Administrative Courts "No later than sixty (60) calendar days after the date of the Notice of Action." Keeping services running is a separate, shorter clock: where the member requests a hearing "not more than ten (10) days after the date of action," services must be reinstated and continued until a final decision. Managed care members must finish the plan's process first — "A member of a Managed Care Organization must exhaust the internal appeals process described at 8.209 prior to requesting a fair hearing."

10 CCR 2505-10 §8.057, Code of Colorado Regulations, Medical Services Board · source